Kornimate/medical-research-clean huggingface dataset:
ranolazine for improving symptoms of palpitations

Conditions: Ischemic Heart Disease

Summary: patients with ischemic heart disease often report multiple symptoms, including angina and palpitations. ranolazine has antiarrhythmic effects which are largely a result of the drug's effect on multiple ion channels. it remains unknown, however, whether the favorable effects of ranolazine on symptoms and arrhythmias are maintained over time. aim of this study is to test the hypothesis that chronic treatment with ranolazine can improve the symptomatic status of patients with ischemic heart disease by reducing the occurrence of palpitations.

background: patients with ischemic heart disease often report multiple symptoms, including angina and palpitations. ranolazine is a novel antianginal and antiischemic drug that reduces intracellular sodium and calcium accumulation during ischemia thus limiting ischemic injury. furthermore, ranolazine has antiarrhythmic effects which are largely a result of the drug's effect on multiple ion channels. it has previously been shown that treatment with ranolazine can reduce the frequency of supraventricular and ventricular tachycardia in the short term. in a subgroup analysis of the merlin-timi 36 trial, the continuous ecgs of 6,351 patients were analyzed. the results showed that, in comparison with placebo, treatment with ranolazine resulted in fewer episodes of ventricular tachycardia that lasted 8 beats or longer (5.3% versus 8.3%; p \<0.001), and in fewer episodes of supraventricular tachycardia (44.7% versus 55%; p \<0.001) and new-onset atrial fibrillation (1.7% versus 2.4%; p=0.08). it remains unknown, however, whether the favorable effects of ranolazine on symptoms and arrhythmias are maintained over time. purpose: the primary objective of this study is to test the hypothesis that chronic treatment with ranolazine can improve the symptomatic status of patients with ischemic heart disease by reducing the occurrence of palpitations.

Eligibility criteria:
inclusion criteria: * symptoms of palpitations * angiographically-proven coronary artery disease * stable conditions * no recent acute coronary syndromes * able to understand and willing to sign the informed consent form * symptomatic patients (palpitation) with stable angina pectoris already on therapy with beta-blockers and/or calcium antagonists. exclusion criteria: * women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours * severe renal failure * severe hepatic failure

Keywords: arrhythmias palpitations
management of sleep apnea patients by a clinical nurse (supernurse)

Conditions: Sleep Apnea Syndromes; Sleep Apnea; Multidisciplinary Communication; Sleep Apnea, Obstructive

Summary: sleep apnea is a prevalent problem and references for the evaluation of this condition often exceeds the sleep clinic's capacity thus creating important delays in the patients' care. the overall goal of this project is to assess the feasibility and the non-inferiority of integrating a clinical nurse, or supernurse, to the initial consultation team. the hypothesis is that the integration of a clinical nurse to the sleep clinic's evaluation team is non inferior in terms of patients' outcomes such as improvement of symptoms and quality of life as well as adherence to treatment. this study is supported by funding dedicated to teaching and research activities related to sleep-disordered breathing.


Eligibility criteria:
inclusion criteria: * patients referred to the ''institut universitaire de cardiologie et pneumologie de québec'' 's sleep clinic who have undergone a cardiorespiratory polygraphy. * body mass index (bmi) between 27-35 kg/m2; * apnea-hypopnea index (adi) equal or above 20 events per hour with less than 5 events per hour of central origin; * oxygen desaturaton index (odi) equal or above 10 events per hour; * percentage of time spent below 90% of oxygen saturation equal or less than 10% exclusion criteria : - patients not meeting the above inclusion criteria.
tace combined with rfa/mv treatment in hepatocellular carcinoma beyond milan criterial

Conditions: Hepatocellular Carcinoma

Summary: this study was designed to evaluate the effectiveness of radiofrequency /microwave ablation in patients with hepatocellular carcinoma beyond milan criteria.

the aim of this study is to included 120 patients with intermediate stage hepatocellular carcinoma beyond milan criteria .these patients were randomizedly allocated to tace treatment group or tace+rfa/mv .the treatment effectiveness, local tumor control and survival outcome between the two groups were compared.

Eligibility criteria:
inclusion criteria: * patients diganosed with hepatocellualr carcinoma beyond milan criteria * the presence of a single hcc tumor ≤7 cm in diameter, or multi-nodular hcc tumors (n ≤ 5) small than 7 cm in diameter; * child-pugh a or b * ecog score 0-1; * prothrombin time ≤16 s; * white cell count ≥3,000/mm3, platelet count ≥40 x 109/l;hb≥8.5 g/d; alt/ast≤5×uln;tb≤3mg/dl;alb≥2.8 g/dl ;scr ≤2mg/dl exclusion criteria: * expected survival time \< 12 months before random assignment; * received anticancer surgery or procedure within one month before assignment; * concomitant use of any other anticancer therapy(except immunotherapy and herbal medicine ) ; * existence of portal of hepatic vein invation or extrahepatic metastases;existence of active infection ; * upper gastrointestinal hemorrhage within one month ; .other serious illness or medical condition.
phase ii study, evaluation of safety and efficacy of ides in chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: ides is an immunoglobulin g (igg) cleaving enzyme. it will given to patients with donor specific antibodies to reduce the antibody load and thus enable kidney transplantation. ides antibody reducing efficacy and its safety will be studied.

study 13-hmedides-02 (eudract no. 2013-005417-13) is a single centre, single arm, dose finding, phase ii study in sensitized ckd patients assessing safety, tolerability, pharmacokinetics (pk) and efficacy of hmed-ides without intent to transplantation. however, patients are not removed from the transplant waitlist during the study. included patients has a panel reactive antibody \[pra\] \>70% (n=7).

Eligibility criteria:
inclusion criteria: * diagnosed with chronic kidney disease and in dialysis with identified antibodies against at least two hla antigens of which at least one is 3000 mfi or more as measured by sab assay on at least two occasions. exclusion criteria: * prior malignancy within 2 years excluding adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ and prostate cancer gleason \<6 and prostate-specific antigen (psa) \<10 ng/ml. * any positive result on screening for serum hepatitis b surface antigen, hepatitis c antibody and human immunodeficiency virus (hiv * clinical signs of ongoing infectious disease. * severe other conditions requiring treatment and close monitoring, e.g. cardiac failure \> new york heart association (nyha) grade 3, unstable coronary disease or oxygen dependent chronic obstructive pulmonary disease (copd) * history of any other clinically significant disease or disorder which, in the opinion of the investigator, may either put the patient at increased risk because of participation in the study, or influence the results or the patient's ability to participate in the study * hypogammaglobulinemia defined as any values of p-total igg less than 3 g/l * history of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to ides (e. g streptokinase and/or staphylokinase) * has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 4 months of the first administration of investigational product in this study. patients consented and screened but not dosed in previous studies are not excluded

Keywords: transplantation sensitised patients hla-antibodies
to test for photo allergy reaction of sunscreens

Conditions: Photoallergy

Summary: the primary objective of this tudy was to evaluate the potential of photoallergy of of sun care products sun protection factor (spf) 50 y65 110, spf 50 y51 002, and spf 15 v27 104 application compared to that of a negative control (0.9% sodium chloride, nacl) and followed by irradiation with uv a and uvb. the secondary objective aims for evaluation of the safety of spf 50 y65 110, spf 50 y51 002, and spf 15 v27 104 combined with ultraviolet (uv) a/b irradiation by monitoring adverse events (aes) throughout the study.


Eligibility criteria:
inclusion criteria: * men or women, aged 18 to 65 with good general health * fitzpatrick skin type i iv * females (of childbearing potential) on acceptable measure of contraception * willing to follow study rules, which include: no sun exposure (for example, no swimming, sunbathing, or tanning beds), avoidance of activities that would cause excessive sweating, no use of lotions, creams, or oils on the back area * willing to not change the current brand of personal care products such as soaps, body washes, laundry detergent, body sprays, body spritzes, etc. while participating in the study
maternal and neonatal outcome of pregnant patients with covid-19 in istanbul, turkey: a single-center, retrospective, descriptive study

Conditions: Covid19; Maternal-Fetal Relations

Summary: evaluation of apgar, hemogram and developmental status of babies born from covid 19 positive mothers


Eligibility criteria:
inclusion criteria: * from covid 19 positive mothers * newborn mothers had not other condition or illness exclusion criteria: * from covid 19 negative mothers * childs
metabolic syndrome in early onset versus late onset vitiligo

Conditions: Metabolic Syndrome; Vitiligo

Summary: this study aims at detection of possible associated metabolic syndrome with vitiligo and assessment of possible contribution of the age of onset of vitiligo.

this study aims at detection of incidence of metabolic syndrome in vitiligo patients and possible contribution of the age of onset of the disease. this involves detection of waist circumference, body mass index, index of central obesity, systolic and diastolic arterial blood pressure, fasting blood sugar, high density lipoproteins and triglycerides, in addition to insulin resistance as homeostatic model assessment- insulin resisitance (homa-ir) and serum leptin in vitiligo patients. the outcomes will be correlated to extent/ severity/duration/ activity of vitiligo as well as to the age of onset. this is assumed to be of profound impact on vitiligo patients by properly assessing these patients for associated metabolic risk factors and helping prevent such metabolic derangements by detection of possible contributing factors such as insulin resistance and high serum adipokines as leptin. since there is temporal relation between nutrition, metabolic derangements and skin diseases where nutritional deficiencies as minerals, vitamins and fatty acids can lead to cutaneous manifestations and , on the other hand; skin diseases could contribute to metabolic derangements and nutritional deficiencies, the investigator's study will focus on nutrition and dietary habits and there possible contribution to any associated metabolic risk in vitiligo patients. this is likely to open new horizons in the management of vitiligo, possibly through control of metabolic syndrome risk factors and insulin resistance as well as revealing possible temporal relation to dietary habits that are overlooked in vitiligo patients.

Eligibility criteria:
inclusion criteria: * both genders * patients with non-segmental vitiligo (nsv) and segmental vitiligo exclusion criteria: * smoking * pregnancy * systemic steroid intake in the last 6 months

Keywords: insulin resistance
studying the influence of exposure to maternal voice on oral feeding volumes in preterm infants

Conditions: Enteral Feeding

Summary: oral feeding is one of the primary functions of the neonatal brain. in preterm infant population, competency at oral feeding is one of the major milestones in preparation for discharge. mother's voices have been shown to have a net stimulatory effect and premature infants have been found to have increased cardiorespiratory stability after listening to mother's voices. main objective of this study is to determine if it is possible to expose preterm infant in a systematic manner to mother's voices before their feeds and to determine if this exposure results in an increase in their oral intake.

achievement of full oral feedings is directly associated with length of neonatal intensive care unit stay. extremely low gestational age infants with dysfunctional oral feeding in early childhood have lower cognitive and language skills compared with those with normal oral feedings. also, previous studies have shown a strong association between oral feeding and infant maturity and behavior state and positive feeding experience. in recent years, there is emerging evidence that non-medical developmental care interventions in the neonatal intensive care units such as kangaroo care, single family rooms, and music and massage therapy may be beneficial for preterm infants and improve their long term neurodevelopmental outcomes. beneficial effects of exposure to mother's voice and sounds on preterm infants in the neonatal intensive care units are well documented. our study proposes to examine the association between exposure to mother's voice prior to and during oral feeding and oral feeding volume and rate in preterm infants.

Eligibility criteria:
inclusion criteria: * preterm infants born between gestational age of 28 0/7 weeks and 34 6/7 weeks * ready to start oral feeding attempts * taking a total daily oral intake \< 50% of feeds on average in 2 days prior to starting intervention * mothers who are english speaking and over 18 years old exclusion criteria: * major congenital anomalies * non-english speaking * family history of suspected congenital hearing loss * failed hearing test in nicu * grade three to four intraventricular hemorrhage or periventricular leukomalacia * necrotizing enterocolitis requiring treatment * congenital infections such as cytomegalovirus which can lead to sensorineural hearing loss

Keywords: maternal voice
platelet-rich fibrin in intraoral soft tissue regeneration

Conditions: Mucosal Ulceration

Summary: determine if the use of platelet rich fibrin (prf) improves the rate and quality of healing for intraoral mucosal and epithelial soft tissue defects.


Eligibility criteria:
inclusion criteria: * three categories of patients will be included in this study: 1. osteoradionecrosis (orn) or medication related osteonecrosis of the jaw (mronj) patients who present to clinic with exposed bone and no clinical sign of infection. 2. patients having an excisional biopsy in clinic performed under local anesthesia resulting in a defect that cannot be easily repaired without compromising normal anatomy or function. these situations include excisions which would result in primary closure under tension or with distorted anatomy, require a local flap, or require healing by secondary intention. 3. patients presenting to the post-operative clinic with intraoral surgical wound dehiscence or an intraoral surgical wound healing by secondary intention. exclusion criteria: * patients under 18 years of age. * patient's unable to participate in blood draw either due to medical compromise, inability to tolerate the procedure, or inability of the physician to successfully draw the blood at the time of appointment.

Keywords: platelet rich fibrin (prf)
chemotherapy/radiotherapy versus concomitant chemotherapy followed by radiotherapy in stage iiib non-small cell lung cancer

Conditions: Non Small-cell Lung Cancer

Summary: randomized study in 2 arms, without any masking in patients with non small cell lung cancer, histologically or cytologically confirmed, not liable to surgery, stage iiib or iiia, according to the tnm classification of the american joint committee for cancer. in one arm will be administered concomitant radiotherapy and carboplatin-docetaxel-gemcitabine followed by docetaxel and, in the other arm will be administered docetaxel-gemcitabine followed by concurrent radiotherapy with carboplatin-docetaxel


Eligibility criteria:
inclusion criteria: * unresectable stage iiia or b nsclc patients * who ps 0 or 1 * weight loss \< 5 % within the last 3 months * at least one measurable lesion * planning ct scan previous to randomization * written informed consent exclusion criteria: * malignant effusion, supraclavicular node or svcs * ptv \> 2000 cm3 * v20 \> 35% * fev1 and dlco both \< 30% or 1 liter at study entry

Keywords: lung docetaxel gemcitabine carboplatin radiotherapy
efficacy and safety on the use of bisphosphonates in paediatrics

Conditions: Bone Fragile; Bisphosphonate-Associated Osteonecrosis; Children; Adverse Events

Summary: the investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone during the growth period with few adverse events.


Eligibility criteria:
inclusion criteria: * be under 18 years of age * have been treated by intravenous bisphosphonates for primary or secondary osteoporosis exclusion criteria: * be over 18 years of age
screening protocol for research participants

Conditions: Schizophrenia; Substance Abuse; Cocaine Abuse; Tobacco Use Disorder

Summary: the screening protocol is a system devised to evaluate potential research participants for national institute on drug abuse/maryland psychiatric research center (nida/mprc) studies.

the mprc/nida collaborative research program attempts to: elucidate the nature of serious mental illnesses, drug abuse and addiction; determine the potential use of new therapies, both pharmacological and psychosocial; and decipher the long-term effects of drugs of abuse on the development, maturation, function, and structure of the brain and other organ systems. in support of this work, the scientific goal of this screening protocol is to assess potential research participants' eligibility for research studies. screening will include medical and psychological tests and procedures. the data collected during screening are a unique and valuable source of information that aids in the research mission. therefore, a secondary goal of this protocol is to obtain data that characterizes the population of subjects contacting nida about research participation and to analyze data so obtained, such as that on the prevalence and consequences of hiv/aids, viral hepatitis, and related diseases and issues of selection and sample bias in clinical research. the screening process will be done in two stages, a telephone interview and an in-person evaluation. the telephone interview will last approximately 20 minutes and be conducted solely via the nida call center. answers provided during the phone interview will indicate whether a caller is eligible for in-person screening. those who appear eligible will be given an appointment at either nida or mprc. this protocol pertains only to the in-person participants at mprc. written informed consent will be obtained when the person arrives. the screening process can involve up to 5 visits to mprc.

Eligibility criteria:
inclusion criteria: * age 18 or older * ability to read and understand and answer questions posed. exclusion criteria: * inability to provide valid informed consent * below age 18, and above age 64.

Keywords: screening research participation substance abuse schizophrenia nicotine healthy cigarettes smoking marijuana cocaine
social cognition and interaction training for adults with psychotic disorders: an open pilot study in finland

Conditions: Psychotic Disorder; Cognitive Function 1, Social

Summary: 33 individuals with a psychotic disorder were given 22-24 sessions weekly or twice weekly of social cognition and interaction training (scit) and evaluated at the baseline and after the intervention. main outcome was improvement in social cognition according to specific measures of facial emotion identification, theory of mind, attributional bias, social cognitive accuracy and metacognitive overconfidence.

33 clinically stable in- and outpatients with chart diagnoses of schizophrenia, schizoaffective disorder or unspecified nonorganic psychosis, aged 18-56 years, were given 22-24 weekly or twice weekly sessions of a manualized group treatment for improvement of social cognition, social cognition and interaction training (1,2). main outcome was defined as improvement in social cognition according to specific measures of facial emotion identification, theory of mind, attributional bias, social cognitive accuracy and metacognitive overconfidence.emotion perception was measured with the facial emotion identification task (feit) (3); theory of mind was measured with the hinting task (4) and attributional bias with the ambiguous intentions hostility questionnaire-ambiguous items (aihq-a) (5). in addition, broad-based social cognitive accuracy, attributional bias and metacognitive overconfidence was measured with the social cognition screening questionnaire. all the measures were evaluated at the baseline and immediately after the intervention. changes in total scores for the feit and hinting task, and the three subscales of aihq-a and scsq were analysed separately using paired samples t-test in ibm spss statistics version 21.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of schizophrenia, schizoaffective disorder or psychosis nos * inpatients in longer-stay rehabilitation wards or outpatients in supported housing * stable clinical condition * written informed consent * problems in social relationships according to the clinical staff * standard medical treatment provided by the care facilities exclusion criteria: * inadequate command of finnish language * unstable clinical condition